Bacterial lipopolysaccharide modulates immune response in the colorectal tumor microenvironment

Sulit, A.K.[1,2,*], Daigneault, M. [3], Allen-Vercoe, E. [3], Silander, O.K. [1], Hock, B.[4], McKenzie, J.[4], Pearson, J.[5], Frizelle, F.A. [2], Schmeier, S. [1], Purcell, R. [2]

[1]School of Natural Sciences, Massey University, Auckland, New Zealand

[2]Department of Surgery, University of Otago, Christchurch, New Zealand

[3]Department of Molecular and Cellular Biology, University of Guelph, Ontario, Canada

[4]Haematology Research Group, University of Otago, Christchurch, New Zealand

[5]Biostatistics and Computational Biology Unit, University of Otago, Christchurch, New Zealand

Abstract

Immune responses can have opposing effects in colorectal cancer (CRC), the balance of which may determine whether a cancer regresses, progresses, or potentially metastasizes. These effects are evident in CRC consensus molecular subtypes (CMS) where both CMS1 and CMS4 contain immune infiltrates yet have opposing prognoses. The microbiome has previously been associated with CRC and immune response in CRC but has largely been ignored in the CRC subtype discussion. Using CMS subtyping, we aimed to determine the contributions of the microbiome to the pleiotropic effects evident in immune-infiltrated subtypes. We integrated host gene-expression and meta-transcriptomic data to determine the link between immune characteristics and microbiome contributions in these subtypes and identified lipopolysaccharide (LPS) binding as a potential functional mechanism. We identified candidate bacteria with LPS properties that could affect immune response, focusing on *Fusobacterium periodonticum* and *Bacteroides fragilis* in CMS1, and *Porphyromonas asaccharolytica* in CMS4. Treatment of peripheral blood mononuclear cells (PBMCs) with LPS isolated from these bacteria showed that *F. periodonticum* stimulates cytokine production in PBMCs while both *B. fragilis* and *P. asaccharolytica* had an inhibitory effect. Furthermore, LPS from the latter two species can inhibit the immunogenic properties of *F. periodonticum* LPS when co-incubated with PBMCs. We propose that different microbes in the CRC tumor microenvironment can alter the local immune activity, with important implications for prognosis and treatment response.

Introduction

Colorectal cancer (CRC) tumors consist of a complex microenvironment whose characteristics affect the tumor's progression, prognostics, and therapy response (1,2). The immune-cell infiltrate within the microenvironment plays a key role in CRC as it can either enhance or inhibit tumor development. The induction of a tumor-directed immune response can result in the influx of effector cells and subsequent tumor cell death. However, in other contexts, the tumor itself may subvert the immune response and rather than eliminating the tumor, immune infiltrates may contribute to chronic inflammation and provide signals for cell growth and vascular changes (2,3). Different cytokines and T-cell subsets have been shown to be capable of both promoting or inhibiting cancer progression, and this likely reflects differences in the immunoregulatory signals provided by different tumor microenvironments.

Due to CRC heterogeneity, several different subtyping classifications have been proposed (4–9). Two subgroups are commonly identified among these different schemes, one characterized by microsatellite instability (MSI) and immune activation, and the other defined by angiogenic and mesenchymal characteristics (7). The Colorectal Cancer Subtyping Consortium combined data from several large subtyping studies to generate a classification system of four consensus molecular subtypes (CMS), based on gene expression data (5). Subsequent studies of the immune phenotypes associated with each of these molecular subtypes revealed substantive differences in the composition of the immune infiltrates, with the good prognosis CMS1 (MSI-Immune) being immunogenic and the poor prognosis CMS4 (mesenchymal) being inflamed and characterized by immunosuppression (10–12).

Understanding immune responses in CRC is not complete without consideration of the microbiome, as evidenced by lower tumor susceptibility in germ-free rats compared to conventional rats upon carcinogen introduction (13,14); differences in tumor susceptibility between mice with different microbiome communities (15); and differences in microbiomes of cancers with deficient or proficient mismatch repair functions (16). Bacteria such as *Fusobacterium nucleatum, Porphyromonas asaccharolytica,* and *Parvimonas micra* have been identified as potential biomarkers in studies of CRC (17,18). Taxa associated with the oral cavity have also been found to be enriched in CRC (18–21), possibly driving the increase seen in species richness (18). Of the microbial functional pathways that have been associated with CRC, many involve immune responses. *F. nucleatum* subspecies *animalis* can induce CCL20, a chemokine that plays a role in recruitment of Th17, regulatory T-cells, and dendritic cells (22), while Enterotoxigenic *B. fragilis* (ETBF) toxin is associated with murine colon tumor formation, through activation of signal transducer and activator of transcription-3 (STAT3) with Th17 responses, also involving IL-17 and IL-23 (23).

The CMS1 and CMS4 subtypes differ with respect to both their immune composition and prognoses. Although the microbiome is known to be a strong modulator of immune responses, its potential role in driving the differing immune compositions of CMS1 and CMS4 subtypes is yet unexplored. In this study we analyzed the microbiome composition in each subtype and detected differences in microbiome signatures associated with different patterns of immune activation in CMS1 and CMS4. We therefore aimed to determine how microbes from different

subtypes of CRC tumors could potentially affect the immune environments characteristic of these respective tumors.

Methods

Sample Collection and Handling

A total of 308 samples were collected during surgical resection of colorectal tumors from patients who had not received chemotherapy prior to surgery. Patients with diagnosed HNPCC or FAP were excluded. All participants provided written, and informed consent and the study was approved by the University of Otago Human Ethics Committee with approval number ***H16/037.*** During surgery, samples were taken, frozen in liquid nitrogen, and stored at -80^{0}C. Before RNA extraction, samples were first equilibrated for at least 48 hours at -20^{0}C in RNAlater ICE^{TM} (Qiagen).

RNEasy Plus Mini Kit (Qiagen) was used to extract RNA from 15-20mg of tissue, disrupted using a Retsch Mixer Mill, including a DNAse treatment step in the procedure. Purified RNA was quantified using a NanoDrop 2000c spectrophotometer (Thermo Scientific, Asheville, NC, USA) and subsequently stored in -80^{0}C.

RNA Sequencing

Library preparation for RNA sequencing was carried out using the Illumina TruSeq Stranded Total RNA Library preparation kit (Illumina), with ribosomal RNA depletion using Ribo-Zero Gold. The Illumina Hi-Seq 2500 V4 platform was used for RNA sequencing, producing 125 bp

paired-end reads. Each sample library was split into lanes to avoid technical bias and were later merged during the data processing phase. Merged raw data can be found under Bioproject ID PRJNA788974 in the NCBI SRA database.

Consensus Molecular Subtype Classification

Fastq-mcf from ea-utils (24,25) and SolexaQA++ (26) were used for quality control and trimming of reads before merging of sequences from different lanes. Salmon (27) was then used to quantify transcript expression. The publicly available CRC CMS classifier (5) was used to categorize samples into one of four CMSs. Of the 308 samples, 260 were classified into a CMS, with 60 samples in CMS1, 145 in CMS2, 38 in CMS3, and 17 in CMS4. For subsequent analysis, we focused on the 260 classified samples.

Bioinformatics Analysis

After trimming, the 260 samples were run through the MetaFunc pipeline (28) using default settings, except for setting reverse stranded option for featureCounts (29), and a species needing at least 0.01% abundance in at least one of the 260 samples to be included in the microbiome analysis. Databases used were those provided in https://metafunc.readthedocs.io/en/latest/usage.html#databases.

Differential Expression and Gene Set Enrichment Analysis in Host

From the results of the MetaFunc analysis, we gathered the host-gene expression raw counts table into a matrix for input into *DESeq2* (30) with metadata information on their respective CMS. Using the 260 samples that had been classified into a subtype, *DESeq2* was used to obtain

differentially expressed genes (DEGs) in one CMS compared to the average of the other three subtypes. Genes were considered differentially expressed if their Benjamini-Hochberg (BH) adjusted p-values were < 0.05. Raw p-values and log-fold change generated through *DESeq2* were then used for ranking and sign information, respectively, in gene set enrichment analysis (GSEA) using the *clusterProfiler* package (31) with the C5 Ontology Gene Sets collection (version 7) from the molecular signatures database (MSigDB) (32,33). We considered a gene set enriched in a subtype if it had adjusted p-values of <0.05 and positive Normalized Enrichment Score (NES). We interrogated the enriched gene sets in the CMS subtypes using immune-related keywords as follows: "IMMUN", "T CELL", "INTERFERON", "CYTOKINE", "TOLL LIKE", "LYMPHOCYTE", "LEUKOCYTE", "PATTERN RECOGNITION", "LIPOPOLYSACCHARIDE", "MHC", "INFLAMMATORY", "ANTIGEN", "INTERLEUKIN", and "BACTERIA".

Detailed host analysis may be found at https://gitlab.com/alsulit08/2021_uoc_massey_lps-crc/-/tree/master/Bioinformatics.

Differential Abundance of Microbes in the Microbiomes of CRC Subtypes

From the results of the MetaFunc analysis, raw counts of microbial taxonomies were gathered into a Phyloseq object (34), with metadata information on their respective CMS. *DESeq2* was used to identify differentially abundant microbes in either CMS1 or CMS4 compared to the average of the other three subtypes. Microbes were considered differentially abundant in a CMS if they had a $\log_2$ fold change > 0 and adjusted p-value < 0.05.

Lipopolysaccharide-associated Bacteria

MetaFunc produces a table that indicates which bacterial taxonomy IDs have proteins that are annotated with gene ontology terms. All bacterial species with proteins annotated with "lipopolysaccharide biosynthetic process" or "lipid A biosynthetic process" were obtained for CMS1 and CMS4 samples, and then cross-referenced with differentially abundant microbes in CMS1 or CMS4, respectively, to obtain a list of differentially abundant bacteria that have proteins annotated with LPS-related processes.

Lipopolysaccharide from Bacterial Strains

LPS was extracted from strains of *Fusobacterium periodonticum* (*1/1/54 (D10), 2/1/31,* and *1/1/41 FAA*), *Bacteroides fragilis* (*3/2/5, 2/1/16,* and *2/1/56 FAA*), and *Porphyromonas asaccharolytica* (*CC44 001F, and CC1/6* F2) using Bacterial Lipopolysaccharides (LPS) Extraction Kit (Alpha Diagnostic International, Catalog # 1000-100-LPS) as per the manufacturer's instructions, resulting in a final yield of 30 µg/mL of LPS.

PBMC Treatment with LPS from Bacterial Species

PBMCs ($2x10^5$ cells) were incubated with LPS preparations (at least 16h) of varying concentrations (600 ng/mL, 60 ng/mL or 6 ng/mL) from *B. fragilis* (*3/2/5, 2/1/16,* and *2/1/56 FAA*), *F. periodonticum* (*1/1/54 (D10), 2/1/31,* and *1/1/41 FAA*) or *P. asaccharolytica* (*CC44 001F, and CC1/6* F2) at concentrations of 600, 60, or 6 ng/mL. For co-incubation tests, we used *B. fragilis* strain *2/1/16, F. periodonticum* strain *2/1/31*, and *P. asaccharolytica* strain *CC1/6 F2*. We treated the PBMCs with 6 ng/mL of *F. periodonticum* (strain *2/1/31*) LPS and 600 ng/mL of *B. fragilis* (strain *2/1/*16) or *P. asaccharolytica* (strain *CC1/6 F2*) LPS. As no-treatment controls,

PBMC medium (RPMI, 10%FCS, 1% glutamine, 0.2% Penicillin/Streptomycin) or RPMI alone was added to the initial culture of PBMCs. Co-incubation experiments were conducted at least three times. For each repeated experiment, PBMCs were obtained from a different individual.

Measurement of Cytokine Production and Statistical Analysis

Secreted cytokine expression was measured using LegendPlex Human Inflammation Panel 1 (Cat no. 740809) on a Beckman Coulter Cytomics FC500 Flow Cytometry Analyzer, following the manufacturer's instructions. For all runs, baseline values of the cytokines from untreated PBMCs were obtained. Legendplex Software (Windows version 8 or MacOS version 7.1, using the 5-parameter curve fitting model) was used to assess final concentrations of the cytokines of interest. Paired student's t-tests were used to test for differences in cytokine production between baseline PBMC and *F. periodonticum* treatment, and *F. periodonticum* treatment and *F. periodonticum* with either *P. asaccharolytica* or *B. fragilis* treatment. Effect Sizes were obtained using Cohen's d, with Hedges correction, to account for small sample sizes.

Detailed analyses may be accessed at https://gitlab.com/alsulit08/2021_uoc_massey_lps-crc/-/tree/master/LPS_Experiments

Results

CMS1 and CMS4 have Enriched Gene Sets Involved in Immune Response

In order to compare which gene sets were enriched in different subtypes of CRC, we first used DESeq2 to compare gene expression in CMS1 samples with the average of the CMS2, CMS3 and CMS4 samples. There were 4736 genes that were significantly over expressed (adjusted p-value < 0.05) in CMS1 compared to the other subtypes. We carried out gene-set enrichment analysis (GSEA) on the list of genes as described in the methods section, and obtained those with positive normalized enrichment scores (NES) as gene sets enriched in CMS1. We obtained a total of 318 gene sets that had positive NES in CMS1, with adjusted p-value < 0.05. Several of the most enriched gene sets were related to immune responses (cytokines, antigen processing and presentation, and cell killing processes) as well as nuclear organization and replication processes. We therefore subset the enriched gene sets in CMS1 using immune-related keywords (see **Methods**). As it has been theorized that microbes might affect the balance of immune responses in the tumor microenvironment (TME), we sought to identify if response to microbes is captured among the enriched gene sets of our subtypes by including "BACTERIA" in the keywords.

We performed the same analyses for CMS2, CMS3, and CMS4, against the average of the other three subsets. We obtained no enriched gene sets using the immune-related keywords above in CMS2 and CMS3, consistent with previous studies describing these as "immune-neglected" (35). There were 2481 DEGs in CMS4 compared to the other subtypes. The top enriched gene

22 sets for CMS4 primarily comprised terms corroborating its epithelial-mesenchymal-transition
23 (EMT) and angiogenic characteristics. As studies have suggested a role for immune cells in
24 immunosuppression in CMS4 (10–12), we examined the 1142 enriched gene sets in CMS4, and
25 found 59 enriched gene sets that contained immune-related keywords.
26
27 We found an overlap of enriched immune-related gene sets between CMS1 and CMS4 (**Figure**
28 **1A**). These included production of Interleukin 6, cytokine secretion, and T-cell activation, all of
29 which could lead to immune-induced cytotoxic activity that could destroy cancer cells, or
30 chronic inflammation and escape in favour of cancer progression (3,36–38). Some gene sets
31 had prominently higher enrichment scores in CMS1 compared to CMS4; among these was the
32 gene set for T-cell activation. T-cell infiltration in CRC has been associated with better survival
33 (39,40). We also found *Response to Molecule of Bacterial Origin* among these enriched gene
34 sets, indicating the role microbes likely play in the characteristics of these subtypes.
35
36 We found 79 immune-related gene sets unique to CMS1. Several of these (e.g. antigen
37 processing and presentation, MHC protein complex) indicate increased levels of antigen
38 presentation, an early critical process in the induction of antitumor responses (41). Gene sets
39 indicating activity of natural killer cells and production and response to interleukins, including
40 Interleukin-12 and Interleukin-1 beta, were also unique to CMS1 (**Figure 1B**), in addition to a
41 wide array of functions indicating regulation and homeostasis of immune responses, including
42 regulation of apoptosis of leukocytes, lymphocytes, and T-cells. Genes associated with Toll-like

43 receptor activity and lipopolysaccharide signaling pathways were also identified in CMS1, again

44 suggesting that bacteria and their LPS may play a role in the responses observed.

45

46 CMS4 had 34 unique immune related enriched gene sets, several of which are associated with

47 negative regulation of T-cells and other immune responses (**Figure 1C**). Lipopolysaccharide

48 binding was also enriched in CMS4, suggesting a link to bacterial regulation, as seen in CMS1.

49



Figure 1. **Immune Related Enriched Gene Sets in CMS1 and CMS4. A.** Immune related enriched gene sets common to CMS1 and CMS4. **B.** Representative enriched immune-related gene sets unique to CMS1. **C.** Representative enriched immune-related gene sets unique to CMS4.
NES = normalized enrichment score. *Gene Ratio* = genes contributing to enrichment of the gene set from our dataset divided by total set size of the gene set in question. All gene sets have adjusted *p-values* < *0.05*.

50

51 ***Differentially abundant bacteria that contribute to LPS biosynthetic processes in CMS1 include***

52 ***Fusobacteria and Bacteroides fragilis species***

53 From sequencing reads that did not map to the human genome, we obtained matches to

54 microbial species. We found 296 microbial species that were differentially more abundant (DA)

55 in CMS1 compared to the other CMS subtypes (p. adjust < 0.05). As our host GSEA had
56 identified a 'response to microbes' among the enriched gene sets in CMS1 and CMS4, and that
57 these may be related to LPS processes, we selected for bacteria that had proteins annotated
58 with "Lipid A Biosynthetic Process" or "Lipopolysaccharide Biosynthetic Process" Gene Ontology
59 terms, which identified 20 bacterial species in CMS1 (**Figure 2A, left**). Notably, we identified
60 *Fusobacterium* and *Bacteroides* as among the abundant bacteria with LPS processes. These two
61 genera have previously been implicated in the progression of CRC (17,22,23,42). We focused on
62 *F. periodonticum* and *B. fragilis* to further investigate the potential interaction between their
63 LPS molecules and immune responses in host cells (**Figure 2B**).
64
65 In contrast, only 127 microbes were found to be differentially more abundant in CMS4
66 compared to the other three subtypes, and only three bacterial species had proteins annotated
67 with LPS or Lipid-A biosynthetic processes (**Figure 2A, right**). Of these, we chose
68 *Porphyromonas asaccharolytica* to investigate further for its effects on immune response in *in*
69 *vitro* experiments, as *P. asaccharolytica* has been identified as a CRC marker in multi-cohort
70 analyses (17,18).
71



Figure 2. Abundant Microbes in CMS1 and CMS4 with lipopolysaccharide processes. A. Differentially abundant Bacteria in CMS1 and CMS4 with LPS processes annotations, showing their fold changes in CMS1 (left) or CMS4 (right) against the average abundance of the other three subtypes. **B.** *F. periodonticum* and *B. fragilis* normalized counts in CMS1 compared to the other subtypes.
log2FC = $\log_2$Fold Change

72

73 ***LPS from different bacterial species have different effects on cytokine release***

74 Stock cultures of peripheral blood mononuclear cells (PBMCs) were incubated with increasing

75 concentrations of LPS, extracted from *F. periodonticum (*strains *1/1/54 (D10), 2/1/31, and*

76 *1/1/41 FAA) , B. fragilis (*strains *3/2/5, 2/1/16, and 2/1/56 FAA),* or *P. asaccharolytica (*strains

77 *CC44 001F,* and *CC1/6 F2)* overnight. The concentrations of cytokines present in the

78 supernatants were then analysed by flow cytometry and compared to untreated PBMCs. We

79 focused on IFN-γ, IL-6, IL-10, IL-12p70, IL-1β, and IL-18, as these were prominent cytokines
80 identified in our gene-set enrichment analysis; IL-18 has been found to synergise with IL-12 to
81 increase production of IFN-γ in T-cells (43) and IL-10 is known as a regulatory cytokine
82 (37,38,44). All strains of a given species had similar effects on cytokine production.
83
84 The highest concentration of LPS tested from *B. fragilis* or *P. asaccharolytica* (600 ng/mL) was
85 found to inhibit the release of the measured cytokines, compared to untreated PBMCs. Lower
86 concentrations of LPS from these species also caused a decrease in cytokine production, but to
87 a lesser degree (**Figures S1A and S1B**). Conversely, LPS from *F. periodonticum* strains showed
88 stimulatory effects on the cytokines of interest, with low concentrations of LPS (6 ng/mL)
89 causing an increase in their secretion compared to baseline PBMC levels (**Figure S1C**). No
90 further increases were observed at higher LPS levels.
91
92 As all strains exhibited the same properties (**Figure S1**), we chose a single strain from each
93 species, *F. periodonticum 2/1/31, B. fragilis 2/1/16,* and *P. asaccharolytica CC1/6 F2,* to use in
94 subsequent experiments.
95

96 ***B. fragilis and P. asaccharolytica LPS exhibit immunoinhibitory properties when co-cultured***

97 ***with stimulatory LPS from F. periodonticum***

98 To further investigate the immune modulatory effects of different LPS, we tested whether LPS

99 from *B. fragilis 2/1/16* or *P. asaccharolytica CC1/6 F2* could retain their immunoinhibitory

100 effects on PBMCs when co-cultured with LPS from immunostimulatory *F. periodonticum 2/1/31.*

101

102 PBMCs were incubated with either *F. periodonticum* LPS alone, or in combination with either *B.*

103 *fragilis* or *P. asaccharolytica* LPS, and cytokine production was measured. **Figure 3** and **Figure**

104 **S2** show that the increased cytokine production observed in the presence of *F. periodonticum*

105 LPS alone was attenuated by co-incubation with LPS from *B. fragilis* or *P. asaccharolytica*. In

106 **Figure 3,** we show that *B. fragilis* or *P. asaccharolytica* LPS, when co-cultured with LPS from *F.*

107 *periodonticum,* reduced cytokine secretion towards baseline levels in IL-18, IL-10, and IL-1β.

108 These cytokines are considered protective against CRC, a regulatory cytokine, and detrimental

109 in CRC, respectively. This reduction was significant for IL-1β, and IL-18 when *B. fragilis* LPS was

110 co-incubated with *F. periodonticum* LPS (**Figure 3A and C**),and significant for all three cytokines

111 when *P. asaccharolytica* LPS was co-incubated with *F. periodonticum* LPS (**Figure 3A, B, and C**).

112 All significant comparisons had absolute effect sizes (Cohen's d) greater than 0.8, indicating

113 large effects (**Tables S1 and S2**).

114



Figure 3. Changes in cytokine expression in peripheral blood mononuclear cells (PBMC) following treatment with *F. periodonticum* alone (red), or in combination with *B. fragilis* (blue) or *P. asaccharolytica* (yellow) for cytokines IL-18, IL-10, and IL-1β. For these experiments we used the lowest concentration of *F. periodonticum* LPS (6 ng/mL) and the highest concentration of LPS from *B. fragilis* or *P. asaccharolytica* (600 ng/mL), as these respective concentrations had the largest effects on cytokine production in earlier experiments. Values are shown as percentages of PBMC baseline secretion, which is set at 100%. Dashed lines indicate a single experimental run. Colored, solid horizontal lines represent the means of repeat experiments. Y-axes of IL-10 and IL-1β are in $\log_{10}$ scale, while Y-axis of IL-18 is in the linear scale. *Fpe = F. periodonticum* (6ng/mL), *Fpe + Bfr = F. periodonticum* (6ng/mL) + *B. fragilis* (600ng/mL), *Fpe + Pas = F. periodonticum* (6 ng/mL) + *P. asaccharolytica* (600 ng/mL)*; * = p-value < 0.05 (F. periodonticum vs PBMC, F. periodonticum + B. fragilis vs F. periodonticum* alone*, or F. periodonticum + P. asaccharolytica vs F. periodonticum* alone*).*

115

116 **Discussion**

117 We combined gene-expression data from both tumor and associated microbiota to better

118 understand how the microbiome could influence the differences seen in immune responses in

119 CRC, in a way that could be tested *in vitro*. Several previous studies attributing function to the

120 microbiome have largely been associative (17,18,45), and while important analytical results

121 regarding functional contributions of the microbiome had been made, these have seldom been

122 linked to host gene expression and functional contributions. Here, we show a potential link

123 between enriched microbial species and immune responses seen in CRC, through the action of

124 bacterial lipopolysaccharide.

125 Studies of immune responses in CRC have reported conflicting findings, where they can either
126 induce tumor regression or lead to cancer progression. This delicate balance between pro- and
127 anti-tumor effects is reflected in the consensus molecular subtypes (CMS) of CRC (5), with good
128 prognosis CMS1 and poor prognosis CMS4 having immune infiltrates of differing compositions
129 (10–12). Our analysis of host gene sets confirms previously published reports that CMS1 and
130 CMS4 are immune infiltrated and inflamed, respectively, while CMS2 and CMS3 have little
131 immune activation (35). Enriched gene sets unique to CMS1 involve antigen presentation and
132 processing, natural killer cell activity, and homeostasis of immune responses, and regulation of
133 T-cell apoptosis. These processes, as well as their regulation may affect how CMS1 tumors
134 progress. Enriched gene sets in CMS4 meanwhile indicate an association with
135 immunosuppression, consistent with previous studies (2,10)
136
137 Among the enriched immune gene sets common to CMS1 and CMS4, we identified those
138 related to response to microbes and lipopolysaccharide, indicating a potential role for the
139 microbiome in the characteristics of these subtypes. Focusing on bacteria in the tumor
140 microenvironment with proteins annotated with LPS biosynthetic processes identified *F.*
141 *periodonticum* and *B. fragilis* as differentially abundant in CMS1, and *P. asaccharolytica*
142 differentially abundant in CMS4. *B. fragilis* was among the most enriched bacterial species in a
143 multi-cohort analysis of CRC (17), while toxigenic strains of the bacteria are associated with
144 immune activation, reactive oxygen species (ROS) production and DNA damage, as well as E-
145 cadherin cleavage leading to cell proliferation (23,42). *Fusobacteria* species have been shown to
146 associate with CRC in a multitude of studies (46) and *F. periodonticum* was reported to be

147 enriched in MMR deficient (dMMR) tumors compared to MMR proficient (pMMR) tumors (16).
148 *P. asaccharolytica,* meanwhile, has been identified as a CRC biomarker in previous studies (Dai
149 et al 2018, Thomas et al 2019).
150
151 As CMS1 and CMS4 are thought to represent tumor-immune inhibitory and stimulatory
152 environments, respectively, we hypothesized that *F. periodonticum* and *B. fragilis* would
153 stimulate anti-tumor cytokines (IFN-γ, IL-12 IL-18), and decrease tumor-promoting cytokines (IL-
154 1β and IL-6) (37,38), while the opposite effect may be seen with *P. asaccharolytica.* However,
155 our results using human PBMCs indicate that *F. periodonticum* LPS stimulated the production of
156 all cytokines of interest, including IL-10, while both *P. asaccharolytica* and *B. fragilis* inhibited
157 the production of all of these cytokines. In addition, LPS from both *P. asaccharolytica* and *B.*
158 *fragilis* could attenuate the immunogenicity of LPS from *F. periodonticum,* indicating that
159 interactions between these microbes may add to the complexity of immune responses.
160
161 Although general attributes such as pro- or anti-tumor have been ascribed to many cytokines in
162 the context of cancer, many cytokines display pleiotropic functions that may have opposing
163 effects in CRC. For instance, decreased levels of IL-1β, along with IL-18, are correlated with
164 increased colitis-associated cancer (CAC) in an inflammasome context (47,48) despite IL-18
165 being commonly viewed as anti-tumorigenic (37,38). IL-6 has anti-tumorigenic properties in the
166 form of priming effector T-cells (36); and unchecked IFN-γ could compromise the colonic
167 epithelial barrier (37,49) allowing an influx of microbiota that could influence cancer

168 progression despite IL-6 being described as pro-tumorigenic, and IFN-γ being protective in CRC
169 (37,38).
170 Our findings further illustrate that the balance and control in cytokine production is critical to
171 determining whether the immune microenvironment is pro- or anti-tumorigenic. The balance,
172 we hypothesise, may be reflected in the interactions we see in response to the bacterial LPS we
173 have tested.
174
175 Although our results with *B. fragilis* LPS were unexpected, as high abundance of *B. fragilis* was
176 associated with the immunogenic CMS1 tumors, previous studies have shown that LPS activity,
177 conserved among the *Bacteroidales* order, can be immunosuppressive and promote immune
178 tolerance to the high microbial load found in the gut, which hosts a complex microbial
179 ecosystem (50). Indeed, species of the *Bacteroides* genus, including *B. fragilis*, have been found
180 to have immunoregulatory properties (51–53).
181
182 Further, it was identified that enterotoxigenic *B. fragilis* could promote colonic tumors and
183 induce inflammatory processes but not its non-toxigenic counterpart (23), indicating that it may
184 be the toxin that is necessary for its inflammatory role and not LPS. We were unable to identify
185 whether the *B. fragilis* in our CRC samples were toxigenic or non-toxigenic, or whether the
186 toxigenic strains were expressing the BFT toxin; the BFT toxin may also only be produced within
187 a certain timeframe during carcinogenesis (54). There is also a possibility of a mixture of non-
188 toxigenic and toxigenic *B. fragilis* in our tumor samples, and this combination may indicate a

189 nuanced balance between LPS and *B. fragilis* toxin, along with the more immunogenic LPS of
190 other microbes such as *F. periodonticum*.
191
192 Our findings indicate that while LPS from *B. fragilis* may be immunosuppressive, interaction
193 with immunogenic molecules produced by the same or other microbes adds a layer of
194 complexity to the balance of immune responses in colorectal cancer. In CMS1, we postulate
195 that this balance skews towards immune activation, contributing to anti-tumor effects and
196 positively affecting prognosis, while the immunosuppressive LPS of *P. asaccharolytica* may
197 contribute to immune evasion and escape of tumors in CMS4.
198
199 The cytokine release-inhibiting capabilities of LPS from *B. fragilis* and *P. asaccharolytica* are
200 notable as previous studies emphasize the pro-inflammatory activities of CRC-associated
201 microbiota (13,23,55–57). While we acknowledge that these events also occur within our tumor
202 samples, we also suggest that microorganisms play a role in immunosuppression, either by
203 aiding the tumor progression through immune evasion and escape, or contributing to
204 homeostasis of immunogenic processes.
205
206 The limitations of the study include the use of PBMCs as a proxy for immune cells in the tumor
207 microenvironment. PBMCs may not adequately reflect the effects of LPS on tumor-infiltrating
208 lymphocytes. In vitro cultures of single cell types do not allow for crosstalk between different
209 cell populations, which would be expected in the complex tumor microenvironment.
210 Furthermore, we acknowledge that while we have tested the effects of LPS from single species

211 and pairs of species, colorectal tumors may harbour up to hundreds of different species, and
212 each may elicit an effect dependent on LPS structure and absolute bacterial counts, which could
213 contribute to the nuanced immune-modulation within the TME. In addition, the effects of LPS
214 may be countered or exacerbated by other known bacterial mechanisms, e.g. bacterial toxins,
215 or as yet undiscovered interactions.

216 **Conclusion**

217 In this study, we identified gene sets involved in immune response to microbial triggers in both
218 CMS1 and CMS4 colorectal cancer subtypes and identified LPS from particular bacterial species
219 that associate with immune responses. In vitro analyses showed that *F. periodonticum* LPS,
220 found in CMS1 tumors, increased production of cytokines IL-1β, IFN-γ, IL-18, IL-10, IL-6, and IL-
221 12p70, while LPS from *B. fragilis*, found in CMS1 tumors, and *P. asaccharolytica* LPS, found
222 mainly in CMS4 tumors, decreased production of these cytokines and could also attenuate the
223 immunogenic effect of *F. periodonticum* LPS. Where most previous studies focus on the
224 inflammation-inducing capabilities of CRC-associated microorganisms, our results indicate that
225 their immunosuppressive potential should not be overlooked and adds another layer of
226 complexity to immune responses in CRC.
227

References

1. Angell HK, Bruni D, Barrett JC, Herbst R, Galon J. The Immunoscore: Colon Cancer and Beyond. Clin Cancer Res. 2020 Jan 15;26(2):332–9.

2. Colangelo T, Polcaro G, Muccillo L, D'Agostino G, Rosato V, Ziccardi P, et al. Friend or foe?: The tumour microenvironment dilemma in colorectal cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2017 Jan 1;1867(1):1–18.

3. Markman JL, Shiao SL. Impact of the immune system and immunotherapy in colorectal cancer. J Gastrointest Oncol. 2015 Apr;6(2):208–23.

4. De Sousa E Melo F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LPMH, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nature Medicine. 2013 Apr 14;19(5):614–8.

5. Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The Consensus Molecular Subtypes of Colorectal Cancer. Nat Med. 2015 Nov;21(11):1350–6.

6. Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value. Kemp C, editor. PLoS Medicine. 2013 May 21;10(5):e1001453.

7. Rodriguez-Salas N, Dominguez G, Barderas R, Mendiola M, García-Albéniz X, Maurel J, et al. Clinical relevance of colorectal cancer molecular subtypes. Critical Reviews in Oncology/Hematology. 2017 Jan;109:9–19.

8. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer. 2014 Feb 1;134(3):552–62.

9. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013 May;19(5):619–25.

10. Becht E, de Reyniès A, Giraldo NA, Pilati C, Buttard B, Lacroix L, et al. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Clinical Cancer Research. 2016 Aug 15;22(16):4057–66.

11. Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nature Reviews Cancer. 2017 Feb;17(2):79–92.

12. Karpinski P, Rossowska J, Sasiadek MM. Immunological landscape of consensus clusters in colorectal cancer. Oncotarget. 2017 Oct 27;8(62):105299–311.

13. Janney A, Powrie F, Mann EH. Host–microbiota maladaptation in colorectal cancer. Nature. 2020 Sep;585(7826):509–17.

14. Reddy BS, Weisburger JH, Narisawa T, Wynder EL. Colon Carcinogenesis in Germ-free Rats with 1,2-Dimethylhydrazine and N-Methyl-N'-nitro-N-nitrosoguanidine. Cancer Res. 1974 Sep 1;34(9):2368–72.

15. Yu AI, Zhao L, Eaton KA, Ho S, Chen J, Poe S, et al. Gut Microbiota Modulate CD8 T Cell Responses to Influence Colitis-Associated Tumorigenesis. Cell Reports. 2020 Apr 7;31(1):107471.

16. Hale VL, Jeraldo P, Chen J, Mundy M, Yao J, Priya S, et al. Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers. Genome Medicine. 2018 Oct 31;10(1):78.

17. Dai Z, Coker OO, Nakatsu G, Wu WKK, Zhao L, Chen Z, et al. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome [Internet]. 2018 Dec [cited 2018 Jul 13];6(1). Available from: https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0451-2

18. Thomas AM, Manghi P, Asnicar F, Pasolli E, Armanini F, Zolfo M, et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat Med. 2019 Apr;25(4):667–78.

19. Loftus M, Hassouneh SAD, Yooseph S. Bacterial community structure alterations within the colorectal cancer gut microbiome. BMC Microbiology. 2021 Mar 31;21(1):98.

20. Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WKK, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nature Communications. 2015 Oct 30;6:8727.

21. Purcell RV, Visnovska M, Biggs PJ, Schmeier S, Frizelle FA. Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer. Scientific Reports [Internet]. 2017 Dec [cited 2018 Jul 13];7(1). Available from: http://www.nature.com/articles/s41598-017-11237-6

22. Ye X, Wang R, Bhattacharya R, Boulbes DR, Fan F, Xia L, et al. *Fusobacterium Nucleatum* Subspecies *Animalis* Influences Proinflammatory Cytokine Expression and Monocyte Activation in Human Colorectal Tumors. Cancer Prevention Research. 2017 Jul;10(7):398–409.

23. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Xinqun Wu, Hung-Rong Yen, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nature Medicine. 2009 Sep;15(9):1016–22.

24. Aronesty E. Comparison of Sequencing Utility Programs. TOBIOIJ. 2013 Jan 31;7(1):1–8.

25. Aronesty E. ea-utils: Command-line tools for processing biological sequencing data [Internet]. 2011 [cited 2022 Nov 3]. Available from: https://github.com/ExpressionAnalysis/ea-utils

26. Cox MP, Peterson DA, Biggs PJ. SolexaQA: At-a-glance quality assessment of Illumina second-generation sequencing data. BMC Bioinformatics. 2010 Sep 27;11(1):485.

27. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nature Methods. 2017 Apr;14(4):417–9.

28. Sulit AKL, Kolisnik T, Frizelle FA, Purcell R, Schmeier S. MetaFunc: Taxonomic and Functional Analyses of High Throughput Sequencing for Microbiomes [Internet]. Bioinformatics; 2020 Sep [cited 2020 Sep 4]. Available from: http://biorxiv.org/lookup/doi/10.1101/2020.09.02.271098

29. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014 Apr 1;30(7):923–30.

30. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. 2014 Nov 17 [cited 2018 Nov 19]; Available from: http://biorxiv.org/lookup/doi/10.1101/002832

31. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters. OMICS. 2012 May;16(5):284–7.

32. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011 Jun 15;27(12):1739–40.

33. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences. 2005 Oct 25;102(43):15545–50.

34. McMurdie PJ, Holmes S. phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data. Watson M, editor. PLoS ONE. 2013 Apr 22;8(4):e61217.

35. Fidelle M, Yonekura S, Picard M, Cogdill A, Hollebecque A, Roberti MP, et al. Resolving the Paradox of Colon Cancer Through the Integration of Genetics, Immunology, and the Microbiota. Front Immunol [Internet]. 2020 [cited 2021 Mar 3];11. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2020.600886/full

36. Fisher DT, Appenheimer MM, Evans SS. The Two Faces of IL-6 in the Tumor Microenvironment. Semin Immunol. 2014 Feb;26(1):38–47.

37. Mager LF, Wasmer MH, Rau TT, Krebs P. Cytokine-Induced Modulation of Colorectal Cancer. Front Oncol [Internet]. 2016 Apr 19 [cited 2018 Oct 16];6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4835502/

38. West NR, McCuaig S, Franchini F, Powrie F. Emerging cytokine networks in colorectal cancer. Nature Reviews Immunology. 2015 Oct;15(10):615–29.

39. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. Science. 2006 Sep 29;313(5795):1960–4.

40. Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361–75.

41. Reeves E, James E. Antigen processing and immune regulation in the response to tumours. Immunology. 2017;150(1):16–24.

42. Goodwin AC, Shields CED, Wu S, Huso DL, Wu X, Murray-Stewart TR, et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proceedings of the National Academy of Sciences. 2011 Sep 13;108(37):15354–9.

43. Tominaga K, Yoshimoto T, Torigoe K, Kurimoto M, Matsui K, Hada T, et al. IL-12 synergizes with IL-18 or IL-1β for IFN-γ production from human T cells. International Immunology. 2000 Feb 1;12(2):151–60.

44. Li J, Huang L, Zhao H, Yan Y, Lu J. The Role of Interleukins in Colorectal Cancer. Int J Biol Sci. 2020 Jun 14;16(13):2323–39.

45. Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med. 2019 Apr;25(4):679–89.

46. Hussan H, Clinton SK, Roberts K, Bailey MT. Fusobacterium's link to colorectal neoplasia sequenced: A systematic review and future insights. World J Gastroenterol. 2017 Dec 28;23(48):8626–50.

47. Allen IC, TeKippe EM, Woodford RMT, Uronis JM, Holl EK, Rogers AB, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. 2010 May 10;207(5):1045–56.

48. Baker KJ, Houston A, Brint E. IL-1 Family Members in Cancer; Two Sides to Every Story. Front Immunol [Internet]. 2019 [cited 2021 Apr 8];10. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2019.01197/full

49. Ferrier L, Mazelin L, Cenac N, Desreumaux P, Janin A, Emilie D, et al. Stress-induced disruption of colonic epithelial barrier: role of interferon-γ and myosin light chain kinase in mice. Gastroenterology. 2003 Sep 1;125(3):795–804.

50. d'Hennezel E, Abubucker S, Murphy LO, Cullen TW. Total Lipopolysaccharide from the Human Gut Microbiome Silences Toll-Like Receptor Signaling. mSystems [Internet]. 2017 Nov 14 [cited 2019 Apr 29];2(6). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686520/

51. Di Lorenzo F, Pither MD, Martufi M, Scarinci I, Guzmán-Caldentey J, Łakomiec E, et al. Pairing Bacteroides vulgatus LPS Structure with Its Immunomodulatory Effects on Human Cellular Models. ACS Cent Sci. 2020 Sep 23;6(9):1602–16.

52. Tan H, Zhao J, Zhang H, Zhai Q, Chen W. Novel strains of Bacteroides fragilis and Bacteroides ovatus alleviate the LPS-induced inflammation in mice. Appl Microbiol Biotechnol. 2019 Mar 1;103(5):2353–65.

53. Yoshida N, Emoto T, Yamashita T, Watanabe H, Hayashi T, Tabata T, et al. Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis. Circulation. 2018 Nov 27;138(22):2486–98.

54. Purcell RV, Pearson J, Aitchison A, Dixon L, Frizelle FA, Keenan JI. Colonization with enterotoxigenic Bacteroides fragilis is associated with early-stage colorectal neoplasia. PLoS ONE. 2017;12(2):e0171602.

55. Chen J, Pitmon E, Wang K. Microbiome, inflammation and colorectal cancer. Seminars in Immunology. 2017 Aug 1;32:43–53.

56. Cremonesi E, Governa V, Garzon JFG, Mele V, Amicarella F, Muraro MG, et al. Gut microbiota modulate T cell trafficking into human colorectal cancer. Gut. 2018 Feb 6;gutjnl-2016-313498.

57. Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013 Aug 14;14(2):195–206.

Declarations

Acknowledgements

The authors would like to thank Helen Morrin at the Cancer Society Tissue Bank, Christchurch, and the patients involved and their whānau for generously participating in this study.

Funding

Maurice and Phyllis Paykel Trust
Gut Cancer Foundation (NZ), with support from the Hugh Green Foundation
Colorectal Surgical Society of Australia and New Zealand (CSSANZ)
The Health Research Council of New Zealand
The funding bodies had no role in the design of the study or collection, analysis, and interpretation of data or in writing the manuscript.